SCHEMBL933209

SCHEMBL933209

COCc1ccc(N(C)C(=O)C(Cl)Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
CYP3A4 P08684 1/20 0.50
KMT2A Q03164 1/20 0.50
HIF1A Q16665 1/20 0.50
HPGD P15428 3/20 0.40
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
RET P07949 2/20 0.39
ACACB O00763 1/20 0.37
MAPT P10636 2/20 0.36
POLB P06746 1/20 0.36
S1PR1 P21453 1/20 0.35
MLYCD O95822 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
CHRNB2 P17787 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20613 0.86 ALDH1A1 (0.49) ALDH1A1CYP3A4KMT2AHIF1AHPGD
Diloxanide SCHEMBL330136 0.79 ALDH1A1 (0.50) ALDH1A1CYP3A4KMT2AHIF1AHPGD
SCHEMBL29287654 0.74 ALDH1A1 (0.49) ALDH1A1CYP3A4KMT2AHIF1AHPGD
SCHEMBL7151472 0.73 PPIB (0.42) ALDH1A1HPGDKDM4ESMN1; SMN2NPC1
SCHEMBL7137957 0.73 PPIB (0.45) ALDH1A1HPGDKDM4ESMN1; SMN2NPC1
Water SCHEMBL11237464 0.73 ALDH1A1 (0.48) ALDH1A1CYP3A4KMT2AHIF1AHPGD
Water SCHEMBL11237487 0.73 ALDH1A1 (0.48) ALDH1A1CYP3A4KMT2AHIF1AHPGD
SCHEMBL11237473 0.72 ALDH1A1 (0.45) ALDH1A1CYP3A4KMT2AHIF1ASMN1; SMN2
SCHEMBL7968199 0.70 ALDH1A1 (0.58) ALDH1A1CYP3A4HPGDKDM4ESMN1; SMN2
SCHEMBL3073313 0.70 KMT2A (0.49) ALDH1A1CYP3A4KMT2AHIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287313-B2 RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-05-14 US claimed
US-20160340382-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2016-11-24 US claimed
EP-2334692-B1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS UNIV MCGILL (CA) 2016-04-13 EP claimed
US-9249175-B2 RNA monomers containing O-acetal levulinyl ester groups and their use in RNA microarrays THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2016-02-02 US claimed
US-20120178638-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-07-12 US claimed
EP-2334692-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS The Royal Institution for the Advancement of Learning / McGill University (CA) 2011-06-22 EP claimed
WO-2010025566-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2010-03-11 WO claimed
US-20240229026-A1 CHIRAL CONTROL WAVE LIFE SCIENCES LTD. (SG) 2024-07-11 US disclosed
WO-2024101446-A1 MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME ルクサナバイオテク株式会社 2024-05-16 WO disclosed
US-20240150756-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-05-09 US disclosed
US-20240117347-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-04-11 US disclosed
EP-4344744-A2 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF Wave Life Sciences Ltd. (SG) 2024-04-03 EP disclosed
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-11-02 US disclosed
US-20120178638-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2012-07-12 US disclosed
EP-2451461-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF Ontorii, Inc (US) 2012-05-16 EP disclosed
US-20110294124-A1 METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS WAVE LIFE SCIENCES LTD. (SG) 2011-12-01 US disclosed
EP-2334692-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS The Royal Institution for the Advancement of Learning / McGill University (CA) 2011-06-22 EP disclosed
WO-2011005761-A1 NOVEL NUCLEIC ACID PRODRUGS AND METHODS USE THEREOF ONTORII, INC (US) 2011-01-13 WO disclosed
WO-2010064146-A2 METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS CHIRALGEN, LTD. (JP) 2010-06-10 WO disclosed
WO-2010025566-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287313-B2 RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays EFTUD2, RNMT, NSUN2 ALDH1A1 199/4885CYP3A4 3560/4885KMT2A 1798/4885
US-20240150756-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RBM17, HNRNPA2B1, HNRNPA1 ALDH1A1 3613/4885CYP3A4 4866/4885KMT2A 1986/4885
US-20160340382-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS EFTUD2, RNMT, RNGTT ALDH1A1 212/4885CYP3A4 3599/4885KMT2A 1746/4885
US-20240229026-A1 CHIRAL CONTROL RNGTT, POLI, NSUN3 ALDH1A1 2867/4885CYP3A4 4157/4885KMT2A 2211/4885
US-20110294124-A1 METHOD FOR THE SYNTHESIS OF PHOSPHORUS ATOM MODIFIED NUCLEIC ACIDS PNP, ADAR, NUDT1 ALDH1A1 4152/4885CYP3A4 4348/4885KMT2A 2183/4885
US-20240117347-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RBM17, HNRNPA2B1, HNRNPA1 ALDH1A1 3613/4885CYP3A4 4866/4885KMT2A 1986/4885
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, RNGTT ALDH1A1 3318/4885CYP3A4 4195/4885KMT2A 1707/4885
US-20120178638-A1 RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS EFTUD2, RNMT, RNGTT ALDH1A1 212/4885CYP3A4 3599/4885KMT2A 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.